丹娜生物：北交所IPO打新冻资6130.17亿元，获配比例0.02%

Core Viewpoint - Danah Biotechnology has successfully completed its IPO on the Beijing Stock Exchange, attracting significant investor interest with a subscription multiple of 4979.02 times and a total of 55.32 million investors participating [1]. Group 1: IPO Details - The effective subscription amount reached 35.849 billion shares, with approximately 613.017 billion yuan of funds frozen [1]. - The allocation ratio for investors was only 0.02% due to the high demand [1]. - Strategic placements included 800,000 shares, accounting for 10% of the total issuance, with a price set at 17.10 yuan per share, raising a total of 13.68 million yuan [2]. Group 2: Company Overview - Danah Biotechnology specializes in the early diagnosis of invasive fungal diseases and other pathogen in vitro diagnostic products, recognized as a manufacturing champion in its field [2]. - The company's diagnostic reagent products are categorized into five major series based on methodology: enzyme kinetics, enzyme-linked immunosorbent assay, immunochromatography, chemiluminescence, and fluorescent quantitative PCR [2]. - Danah has established partnerships with notable companies such as RunDa Medical, Guangzhou Zhenggang, Shandong Huameilun Medical Technology, Suzhou Xinmengxiang Biotechnology, and Shanghai Danli Biotechnology [2]. Group 3: Financial Performance - The company's revenue for the years 2022, 2023, and the first half of 2024 was reported at 295 million yuan, 236 million yuan, and 117 million yuan, respectively [3]. - The net profit attributable to the parent company for the same periods was 44.62 million yuan, 77.60 million yuan, and 38.57 million yuan [3].